Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Pass Above 200 Day Moving Average – Time to Sell?

10 Apr 2026, 23:18 by Renee Jackson · The Cerbat Gem

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Free Report) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.41 and traded as high as $1.70. Lexicon Pharmaceuticals shares last traded at $1.67, with a volume of 2,302,921 shares trading hands.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Citigroup raised their price objective on Lexicon Pharmaceuticals from $2.10 to $2.30 and gave the company a “buy” rating in a research report on Tuesday, March 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, January 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Monday, March 23rd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Lexicon Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $4.15.

Read Our Latest Report on LXRX

Lexicon Pharmaceuticals Trading Down 2.3%

The firm has a market cap of $728.73 million, a P/E ratio of -12.28 and a beta of 0.94. The stock has a fifty day simple moving average of $1.53 and a 200 day simple moving average of $1.42. The company has a debt-to-equity ratio of 0.46, a quick ratio of 4.87 and a current ratio of 4.88.

Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) last posted its earnings results on Thursday, March 5th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. The business had revenue of $5.49 million during the quarter, compared to analyst estimates of $3.14 million. Lexicon Pharmaceuticals had a negative return on equity of 41.94% and a negative net margin of 101.08%. On average, research analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.66 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Lexicon Pharmaceuticals news, Director Invus Global Management, Llc bought 1,538,462 shares of Lexicon Pharmaceuticals stock in a transaction on Monday, February 2nd. The stock was acquired at an average price of $1.30 per share, with a total value of $2,000,000.60. Following the acquisition, the director owned 1,538,462 shares in the company, valued at approximately $2,000,000.60. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Raymond Debbane bought 100,000 shares of Lexicon Pharmaceuticals stock in a transaction on Monday, February 23rd. The stock was acquired at an average cost of $1.47 per share, with a total value of $147,000.00. Following the acquisition, the director owned 1,904,186 shares in the company, valued at approximately $2,799,153.42. This represents a 5.54% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders acquired 1,790,462 shares of company stock valued at $2,369,981. Corporate insiders own 14.00% of the company’s stock.

Institutional Trading of Lexicon Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. R Squared Ltd boosted its stake in shares of Lexicon Pharmaceuticals by 45.3% in the 4th quarter. R Squared Ltd now owns 46,579 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 14,530 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Lexicon Pharmaceuticals by 80.1% in the 3rd quarter. Bank of America Corp DE now owns 57,804 shares of the biopharmaceutical company’s stock worth $78,000 after buying an additional 25,707 shares during the last quarter. Vermillion & White Wealth Management Group LLC boosted its stake in shares of Lexicon Pharmaceuticals by 400.0% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 32,500 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 26,000 shares during the last quarter. Security National Bank of Sioux City Iowa IA purchased a new position in shares of Lexicon Pharmaceuticals in the 4th quarter worth $31,000. Finally, Hudson Bay Capital Management LP purchased a new position in shares of Lexicon Pharmaceuticals in the 2nd quarter worth $26,000. Institutional investors own 74.70% of the company’s stock.

About Lexicon Pharmaceuticals

(Get Free Report)

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.